1. Home
  2. Disease & Disorders
  3. New York, NY
  4. Elton John AIDS Foundation

Elton John AIDS Foundation

Elton John AIDS Foundation is ranked #46 of 51 disease & disorders organizations in New York, NY, with an America's Best Score of 63 out of 100, based on its 2025 Form 990.

  • New York, NY
  • Tax-exempt since 1993
  • EIN: 58-2033460
eltonjohnaidsfoundation.org ProPublica Charity Navigator
Is this your organization? Claim it Tax filings by year Nominate
63OF 100 #46 of 51 in New York ranked disease & disorders organizations How this score is calculated

Organization summary

Elton John AIDS Foundation is a 501(c)(3) organization, classified under Disease & Disorders (NTEE G810). Contributions are tax-deductible.

584 Broadway Rm 1006, New York, NY 10012-5239

Among the 85 scored disease & disorders organizations in New York, Elton John AIDS Foundation holds 11.1 months of operating reserves (peer median 11.2 months), runs a typical yearly surplus of 5.3% (peers: surplus of 0.8%), and has cut spending 4.6% a year (peers: grown spending 6.1% a year).

In fiscal year 2025 it reported $21,226,655 in revenue and $19,445,285 in expenses, with contributions making up 95.7% of revenue.

Work here? Claim this profile to add your mission, programs and logo.

What it does

From its own Form 990, as filed with the IRS

Mission · 2025 Form 990

Established in 1992, the foundation is one of the leading independent AIDS organizations in the world. With the mobilization of our supporters and partners, we fund local experts across four continents to provide care as well as supporting governments to end AIDS.

Main program · fiscal year 2025

  • The Elton John AIDS Foundation is in the top 5 philanthropic funders of HIV/AIDS grants worldwide. Since our founding, we have raised over $660 million to support over 3,236 projects in 108 countries to end AIDS. In 2025, our U.S. And u.k. Entities together reached 523,000 people with HIV services and funded $18,768,059 of new grants. The U.S. Entity alone awarded $11,717,713 of grants and spent $… Read more

    The Elton John AIDS Foundation is in the top 5 philanthropic funders of HIV/AIDS grants worldwide. Since our founding, we have raised over $660 million to support over 3,236 projects in 108 countries to end AIDS. In 2025, our U.S. And u.k. Entities together reached 523,000 people with HIV services and funded $18,768,059 of new grants. The U.S. Entity alone awarded $11,717,713 of grants and spent $16,479,482 on program services, 85% of our total expenses. See schedule o for continuation.Elton John AIDS Foundation inc. Was founded by elton john in 1992 and is governed by a board of philanthropic leaders, technical experts, corporate executives and leaders in the global HIV/AIDS response. In 2020, we embarked on an exciting strategic plan, designed to reduce stigma and HIV transmission, ensure that everyone has access to compassionate care and treatment, and that governments invest equitably in those populations most affected by HIV. Our strategy focuses on reaching the most marginalized populations and communities that are so often left behind and excluded from the HIV response.the Elton John AIDS Foundation's grantmaking is made from both its U.S. Entity (to which this form 990 relates) and u.k. Entity. As reported in the foundation's annual report, available on our website, the foundation awarded 44 new grants to the value of $18,768,059 in 2025, of which $11,717,713 was from the U.S. Entity alone. We reached 523,000 people with services including testing, prevention, treatment, training and education, with grants spanning 68 countries. We initiated 26,857 people on pre-exposure prophylaxis (prep), initiated 20,984 on antiretroviral therapy (art) and supported 230,692 people to test for HIV. Grants were awarded across our strategic portfolio areas:1. Young people: To meet the growing global health needs of young people and prevent a resurgence of the HIV/AIDS epidemic, we are supporting our partners to pilot and scale effective public health responses which meet young people where they are through innovations in service delivery. 2. LGBTQ+: LGBTQ+ groups are at increased risk of HIV infection. We are working to ensure LGBTQ+ people have access to protection and appropriate, quality health care.3. United states of America: The HIV/AIDS epidemic in the united states will not end without concerted action from both the public and private sector. We are strengthening these partnerships to enhance health workforce capabilities, to increase the accessibility and demand for HIV prevention and testing commodities, to enhance linkages to care within communities, and to address national, state, and local policy barriers for people living with HIV and those at heightened risk of infection.4. Eastern europe and central asia: In eastern europe and central asia, HIV infections and aids-related deaths continue to rise, demanding urgent action to turn the tide of the epidemic. To achieve epidemic control in eeca, we are working to improve and expand HIV services for all, to reduce stigma and discrimination experienced by key populations, and to share learning on effective approaches. In response to the outbreak of war in ukraine and increased burdens on the health system, we are making strategic investments to bolster and sustain the HIV/AIDS response during this crisis. 5. People who use drugs: We are working to ensure people who use drugs have access to relevant and effective treatment strategies, and can rely on continued investment to meet their health needs.our current strategic plan will conclude in 2026 and we will use the year to focus on closing out our existing programs strongly and evaluating the successes and learnings from the projects we have funded over the past five years. These insights will inform the new strategy, which is currently being developed with deep engagement from both the board and management and will be implemented from 2027 onward.financial review:the foundation consists of a u.k. Entity and a U.S. Subsidiary entity (to which this form 990 relates), in combination referred to as the "group". The directors manage the grant making, fundraising, and other operations of the organisation jointly across the group. As reported in the annual report available on our website, total combined revenue for the group in 2025 was $25,673,153 (2024: $29,718,676), Thanks to the ongoing success of the rocket fund, our multi-year fundraising initiative designed to accelerate the foundation's life-saving work. This included $21,226,655 of revenue generated in the U.S. Entity alone (2024: $20,298,674). During the year, we announced the expansion of the rocket fund to $200 million, to ensure we can meet rising needs and continue driving impact worldwide. In a year marked by severe funding cuts across global health programs, the foundation remained unwavering in its commitment to the communities most at risk. As reported in the annual report, the group invested $25,796,536 in expenditure on charitable activities in 2025 (2024: $27,885,498) Whilst the U.S. Entity alone spent $16,479,482 on program services (2024: $17,528,743), Representing 85% of total expenses in the entity (2024: 88%). As reported in the annual report, the group recorded a deficit of $6,003,525 (2024: $3,790,670), Resulting in net assets of $23,993,190 at December 31, 2025 ($29,996,715 at December 31, 2024). This reflected our intentional decision to draw on excess reserves built from surpluses in earlier years of the current strategic plan, enabling us to maximize our impact during a challenging period for the sector. At a time when many were scaling back, it was essential that we maintained, and in some cases extended, funding for our partners facing cuts from elsewhere.as reported in this form 990, the U.S. Entity recorded a surplus of $1,781,370 (2024: $303,061), Which together with unrealized gains on investments and other changes in net assets, resulted in net assets of $17,966,810 at December 31, 2025 ($16,050,177 at December 31, 2024). At the end of 2025, the group and U.S. Entity continue to hold robust reserves, ensuring operational stability and positioning us strongly to deliver on our strategy.

    $16,479,482 spent

Where each dollar went · fiscal year 2025

Of every dollar it spent, 85¢ went to programs, 4¢ to management and 11¢ to fundraising.

  • Programs $16,479,482
  • Management $766,087
  • Fundraising $2,199,716

In the organization's own words to the IRS, shown for context. None of this affects the America's Best Score, and a Form 990 describes programs without measuring their results.

America's Best Score

Free assessmentMethodology
Score63 / 100
Rank in New York#46 of 51
DesignationRanked

Score breakdown

MeasureThis organizationPoints
Operating reserves11.1 mo; 4.0 mo in cash7.7 / 25
Financial balance (median margin)+5.3%16.4 / 20
Transparency4 full 990s, latest TY202520 / 20
Program growth−4.6% / yr5.2 / 15
Track record33 years10 / 10
Debt load43.4% of assets3.3 / 10
Total62.6 → 63
Spending on programs
Not scored; America's Best needs 65%+
85%Meets

Compared with New York peers

MeasureThis organizationPeer median
Operating reserves11.1 mo11.2 mo
Typical margin+5.3%+0.8%
Spending growth−4.6% / yr+6.1% / yr
Debt load43.4%7.4%

Peers: the 85 New York disease & disorders organizations with a score, ranked or below the bar.

Tax filings by year

Financial data extracted from the Form 990 the organization filed with the IRS for each fiscal year. Revenue lines can exceed 100% when other items, such as fundraising event costs, are netted against total revenue.

Revenue$21,226,655Fiscal year 20252022: $29,188,89820222023: $21,618,93920232024: $20,298,67420242025: $21,226,6552025
Expenses$19,445,285Fiscal year 20252022: $22,405,99020222023: $22,166,62220232024: $19,995,61320242025: $19,445,2852025
Total assets$31,749,557Fiscal year 20252022: $28,668,78820222023: $36,322,60520232024: $37,404,91720242025: $31,749,5572025
Total liabilities$13,782,747Fiscal year 20252022: $12,818,22620222023: $20,582,31120232024: $21,354,74020242025: $13,782,7472025
Fiscal year ending December 2025
Revenue$21,226,655
Expenses$19,445,285
Net income$1,781,370
Net assets$17,966,810

Notable sources of revenue

Percent of total revenue
Contributions$20,307,545
Program services$0
Investment income$752,761
Other (net)$166,349

Assets / debt

Total assets$31,749,557
Total liabilities$13,782,747
Net assets$17,966,810

Compensation

Not in our extract for this year.

Fiscal year ending December 2024
Revenue$20,298,674
Expenses$19,995,613
Net income$303,061
Net assets$16,050,177

Notable sources of revenue

Percent of total revenue
Contributions$19,104,639
Program services$0
Investment income$1,200,917
Other (net)−$6,882

Assets / debt

Total assets$37,404,917
Total liabilities$21,354,740
Net assets$16,050,177

Compensation

Not in our extract for this year.

Fiscal year ending December 2023
Revenue$21,618,939
Expenses$22,166,622
Net income−$547,683
Net assets$15,740,294

Notable sources of revenue

Percent of total revenue
Contributions$21,038,793
Program services$0
Investment income$589,863
Other (net)−$9,717

Assets / debt

Total assets$36,322,605
Total liabilities$20,582,311
Net assets$15,740,294

Compensation

Not in our extract for this year.

Fiscal year ending December 2022
Revenue$29,188,898
Expenses$22,405,990
Net income$6,782,908
Net assets$15,850,562

Notable sources of revenue

Percent of total revenue
Contributions$29,074,072
Program services$0
Investment income$155,175
Other (net)−$40,349

Assets / debt

Total assets$28,668,788
Total liabilities$12,818,226
Net assets$15,850,562

Compensation

Officers and key employees$341,577
Share of expenses1.5%

About this data

Figures come from IRS Form 990 filings, through the IRS Exempt Organizations Business Master File (2026-11-09) and e-filed returns. Form 990 data typically lags 12–24 months behind an organization's fiscal year. Found an error?